North America Polycystic Ovarian Syndrome Treatment Market Size & Outlook
Related Markets
North America polycystic ovarian syndrome treatment market highlights
- The North America polycystic ovarian syndrome treatment market generated a revenue of USD 2,042.5 million in 2024.
- The market is expected to grow at a CAGR of 6.1% from 2025 to 2030.
- In terms of segment, oral contraceptives was the largest revenue generating drug class in 2024.
- Oral Contraceptives is the most lucrative drug class segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2024 | USD 2,042.5 million |
| Market revenue in 2030 | USD 2,897.5 million |
| Growth rate | 6.1% (CAGR from 2025 to 2030) |
| Largest segment | Oral contraceptives |
| Fastest growing segment | Oral Contraceptives |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral Contraceptives |
Other key industry trends
- In terms of revenue, North America region accounted for 42.6% of the global polycystic ovarian syndrome treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,595.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Polycystic Ovarian Syndrome Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Ferring B.V. | View profile | - | - | - |
| Pfizer, Inc. | View profile | - | - | - |
| Bristol Myers Squibb | View profile | - | - | - |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
North America polycystic ovarian syndrome treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to polycystic ovarian syndrome treatment market will help companies and investors design strategic landscapes.
Oral contraceptives was the largest segment with a revenue share of 105.52% in 2024. Horizon Databook has segmented the North America polycystic ovarian syndrome treatment market based on oral contraceptives covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to North America polycystic ovarian syndrome treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America polycystic ovarian syndrome treatment market databook
-
Our clientele includes a mix of polycystic ovarian syndrome treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America polycystic ovarian syndrome treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America polycystic ovarian syndrome treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
